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Cell surface growth factor receptors couple envi-
ronmental cues to the regulation of cytoplasmic
homeostatic processes, including autophagy, and
aberrant activation of such receptors is a common
feature of human malignancies. Here, we defined
the molecular basis by which the epidermal growth
factor receptor (EGFR) tyrosine kinase regulates
autophagy. Active EGFR binds the autophagy pro-
tein Beclin 1, leading to its multisite tyrosine phos-
phorylation, enhanced binding to inhibitors, and
decreased Beclin 1-associated VPS34 kinase activ-
ity. EGFR tyrosine kinase inhibitor (TKI) therapy dis-
rupts Beclin 1 tyrosine phosphorylation and binding
to its inhibitors and restores autophagy in non-
small-cell lung carcinoma (NSCLC) cells with a
TKI-sensitive EGFRmutation. In NSCLC tumor xeno-
grafts, the expression of a tyrosine phosphomimetic
Beclin 1 mutant leads to reduced autophagy,
enhanced tumor growth, tumor dedifferentiation,
and resistance to TKI therapy. Thus, oncogenic re-
ceptor tyrosine kinases directly regulate the core
autophagy machinery, which may contribute to
tumor progression and chemoresistance.
INTRODUCTION
Epidermal growth factor receptor (EGFR), an oncogenic receptor
tyrosine kinase, links extracellular signals to cellular homeosta-Csis. In normal cells, EGFR signaling is triggered by the binding
of growth factors, such as epidermal growth factor (EGF), lead-
ing to homodimerization or heterodimerization with other EGFR
family members (such as HER2/neu) and autophosphorylation
of the intracellular domain (Lemmon and Schlessinger, 2010).
The phosphotyrosines formed serve as a docking site for
adaptor molecules, which results in the activation of signaling
pathways including the Ras/MAPK pathway, the PI3K/Akt
pathway, and STAT signaling pathways. In tumor cells, the
tyrosine kinase activity of EGFR may be dysregulated by EGFR
gene mutation, increased EGFR gene copy number, or EGFR
protein overexpression, leading to aberrant EGFR signaling
and increased tumor cell survival, proliferation, invasion, and
metastasis (Ciardiello and Tortora, 2008). EGFR signaling is
deregulated in many human cancers, including those of the
lung, head and neck, colon, pancreas, and brain.
The deregulation of EGFR in human cancers has led to the
development of anticancer agents that target EGFR, including:
(1) anti-EGFR antibodies that inhibit ligand binding and (2)
small-molecule receptor tyrosine kinase inhibitors (TKIs), erloti-
nib and gefitinib, that block EGFR intracellular tyrosine kinase
activity. Although the EGFR TKIs have shown limited clinical
benefit in the majority of solid tumors, they are effective in non-
small-cell lung carcinomas (NSCLCs) that harbor specific muta-
tions in the tyrosine kinase domain of EGFR (most commonly,
in-frame deletion in exon 19 around codons 746–750 or single-
base substitution, L858R, in exon 21) (Ciardiello and Tortora,
2008; Lynch et al., 2004; Pao and Chmielecki, 2010). Most
patients with NSCLCs with EGFR mutations initially respond
favorably to erlotinib or gefitinib, suggesting these mutations
drive tumorigenesis. However, among tumors that initially
respond to EGFR TKIs, most eventually acquire resistance, oftenell 154, 1269–1284, September 12, 2013 ª2013 Elsevier Inc. 1269
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Figure 1. EGFR Activation Inhibits Autophagy and Promotes EGFR/Beclin 1 Complex Formation
(A) Representative images of GFP-LC3 puncta (autophagosomes) in A549 NSCLC cells cultured O/N in normal medium, serum-free medium, or serum-free
medium plus EGF (50 ng/ml, 30 min).
(B) Quantitation of GFP-LC3 puncta in conditions shown in (A). Bars are mean ± SEM of triplicate samples (R50 cells analyzed per sample). Similar results were
observed in three independent experiments. ***p < 0.001, one-way ANOVA.
(C) LC3-I/II and p62 western blot analysis in A549 cells in conditions shown in (A).
(legend continued on next page)
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due to the emergence of a secondary mutation, T790M, in the
kinase domain of EGFR (Pao and Chmielecki, 2010).
Several studies have shown that EGFR signaling regulates
autophagy, a lysosomal degradation pathway that functions in
cellular homeostasis and protection against a variety of dis-
eases, including cancer (Levine and Kroemer, 2008). The down-
stream targets of EGFR—PI3K, Akt, and mammalian target of
rapamycin (mTOR)—are well-established negative regulators
of autophagy (Botti et al., 2006). Moreover, EGFR inhibitors
induce autophagy in NSCLCs (Gorzalczany et al., 2011; Han
et al., 2011) and other cancer cells (Fung et al., 2012). However,
the links between EGFR signaling and autophagy remain poorly
understood, particularly (1) the molecular mechanisms by which
EGFR signaling suppresses autophagy, (2) the role of EGFR
suppression of autophagy in lung cancer pathogenesis, and (3)
the role of autophagy induction in the response to TKI therapy.
EGFR inhibitor-induced autophagy in lung cancer cells has
been postulated to exert either cytoprotective (Han et al.,
2011) or cytotoxic (Gorzalczany et al., 2011) effects.
Conflicting results regarding the role of autophagy in the
response or resistance to EGFR TKI treatment reflects broader
uncertainties in the role of autophagy in cancer therapy (Rubinsz-
tein et al., 2012). It is not understood in what contexts autophagy
induction contributes to tumor progression or suppression and
to tumor chemoresistance or chemosensitivity. There is a
general consensus that autophagy prevents tumor initiation,
as loss-of-function mutations of several different autophagy
genes results in spontaneous tumorigenesis (beclin 1, Atg5,
and Atg7) and/or increased chemical-induced tumorigenesis
(Atg4C) in mice (Rubinsztein et al., 2012). Despite this inhibitory
role in tumor initiation, it has been proposed that autophagy may
promote the growth of established tumors and contribute to
chemoresistance, principally through its actions to prolong the
survival of metabolically stressed neoplastic cells (Rubinsztein
et al., 2012).
To understand the relationship between oncogenic signaling,
autophagy, and distinct stages of tumorigenesis, it is important
to define the molecular mechanisms by which oncogenic
signaling regulates autophagy. We recently showed that the
oncogene Akt inhibits autophagy independently of mTOR
signaling via serine phosphorylation of the essential autophagy
protein, Beclin 1 (Wang et al., 2012), a haploinsufficient tumor
suppressor protein frequently monoallelically deleted in human
breast and ovarian cancer (Levine and Kroemer, 2008). More-
over, Akt-mediated phosphorylation of Beclin 1 contributes
to Akt-dependent fibroblast transformation, supporting the
concept that inactivation of Beclin 1-dependent autophagy plays
a role in tumor initiation. However, it is not known whether onco-
genic inactivation of Beclin 1 (or other autophagy proteins) influ-
ences progression of established tumors and/or their response
to therapy.(D) Immunoprecipitation of EGFR with Beclin 1 in A549 NSCLC cells in condition
(E) Colocalization of EGFR and Beclin 1 in EGF-treated A549 cells stably express
medium ± EGF (50 ng/ml, 30 min), fixed, and immunostained with anti-EGFR (gre
(F) Colocalization of active EGFRwith cellular organelles. Cells from (E) were cultur
and antibodies to detect early endosomes (EEA1), late endosomes/lysosomes (L
Scale bars represent 20 mm. See also Figure S1.
CHere, we identify the molecular basis by which EGFR tyrosine
kinase activity regulates autophagy. We show that active EGFR
binds to Beclin 1, leading to its tyrosine phosphorylation, alter-
ation of its interactome, and inhibition of its autophagy function.
A mutant of Beclin 1 containing phosphomimetic mutations in
the EGFR-dependent tyrosine phosphorylation sites enhances
autophagy suppression in EGFR-mutated NSCLC cells, result-
ing in enhanced tumor progression, altered tumor cell differenti-
ation, and partial tumor resistance to EGFR TKI therapy. These
findings demonstrate a heretofore unknown link between onco-
genic receptor tyrosine kinases and the autophagy machinery,
which may contribute to tumor progression and resistance to
targeted therapy.
RESULTS
EGFR Activation Promotes Autophagy Inhibition and
EGFR/Beclin 1 Complex Formation
To evaluate whether EGFR activation inhibits autophagy, we
used a human NSCLC cell line, A549, that express wild-type
(WT) EGFR (VanMeter et al., 2008). We measured autophagy
by examining the subcellular localization of a green fluorescent
autophagy reporter protein, GFP-LC3, and by measuring levels
of LC3-II, the autophagosome-associated lipidated form of
LC3, and p62, an autophagic substrate (Mizushima et al.,
2010). Serum depletion resulted in marked autophagy induction,
as evidenced by an increase in GFP-LC3 puncta (autophago-
somes) per cell, increased LC3-II conversion, and increased
p62 degradation (Figures 1A–1C). EGF addition to the serum-
starved cells for 30 min partially reversed autophagy induction.
To explore the mechanism by which EGFR activation inhibits
autophagy, we investigated whether the EGFR can interact
with Beclin 1, a component of the class III phosphatidylinositol
3-kinase (PI3K) (VPS34) autophagy-inducing complex. During
growth in normal or serum-free media when no EGFR phosphor-
ylation was observed, EGFR did not coimmunoprecipitate with
Beclin 1 (Figure 1D). However, when cells were treated with
EGF and EGFR was phosphorylated, EGFR coimmunoprecipi-
tated with Beclin 1. Thus, active phosphorylated EGFR interacts
with a key component of the autophagy machinery, Beclin 1, in
human NSCLC cells in a ligand-dependent manner.
The EGFR is a cell surface receptor that undergoes ligand-
dependent dimerization, phosphorylation of tyrosine residues
within its cytoplasmic tail, and endocytosis (Lemmon and
Schlessinger, 2010). We examined the colocalization of WT
EGFR and Beclin 1 in A549 cells stably expressing Flag-Beclin
1 (Figure 1E). In the absence of EGF stimulation, almost all
EGFR localized to the cell surface and did not colocalize with
Flag-Beclin 1. In contrast, after EGF stimulation, EGFR was
observed in punctate intracellular vesicles and colocalized with
Flag-Beclin 1. This colocalization required EGFR endocytosis,s shown in (A).
ing Flag-Beclin 1 (A549/Flag-Beclin 1). Cells were cultured O/N in serum-free
en) and anti-Flag to detect Flag-Beclin 1 (red). Yellow indicates colocalization.
ed O/N in serum-freemedium + EGF (50 ng/ml, 30min), stained with anti-EGFR
AMP1), or mitochondria (Tom20). Yellow indicates colocalization.
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and not just receptor homodimerization, as inhibition of EGFR
endocytosis by clathrin siRNA blocked EGFR andBeclin 1 coloc-
alization in EGF-treated A549 cells (Figure S1 available online).
To determine the identity of the intracellular vesicles with
EGFR immunostaining, we evaluated the colocalization of
EGFR with different organelle markers, including EEA1 (an early
endosomemarker), LAMP1 (a late endosome/lysosomemarker),
and Tom20, a mitochondrial marker (Figure 1F). Internalized
EGFR colocalized with EEA1, indicating that the majority of
active EGFR resides in endosomes. We also observed weak
colocalization of EGFR with LAMP1 and Tom20, consistent
with the lysosomal trafficking of endocytosed wild-type EGFR
(Carpenter, 1987) and its reported mitochondrial localization
(Yao et al., 2010).
Together, these data indicate that ligand-dependent EGFR
activation leads to the interaction of EGFR and Beclin 1, which
likely occurs primarily in endosomes.
Active EGFR Mutants Interact with Beclin 1 and Inhibit
Autophagy Independently of mTOR
To further evaluate whether ligand-dependent and -independent
activation of EGFR results in the formation of an EGFR/Beclin 1
complex and autophagy suppression, we used HeLa cells that
express low levels of endogenous EGFR (Figure S2A). HeLa cells
were transfected either withWT EGFR, which requires EGF stim-
ulation for EGFRphosphorylation andactivation, orwith constitu-
tively active mutants of EGFR. WT EGFR coimmunoprecipitated
with Flag-Beclin 1 onlywhen activated (tyrosine-phosphorylated)
by EGF stimulation (Figure 2A). In contrast, an active EGFR
mutant common in NSCLCs, EGFR L858R, coimmunoprecipi-
tated with Flag-Beclin 1 in the absence of EGF stimulation. The
TKI, erlotinib, which binds to the EGFRATP binding site, dephos-
phorylated EGFR and abolished the EGFR/Beclin 1 interaction.
Similar results were also observed with another active mutant
EGFR, EGFRD746–750, also commonly found inNSCLCpatients
(data not shown). Thus, both ligand-dependent stimulation of
WT EGFR and activating mutations in EGFR associated with
NSCLC promote the formation of an EGFR/Beclin 1 complex.
We investigated the effects of active EGFR mutants that
constitutively bind Beclin 1 on autophagy. Both amino acid star-
vation and the ATP-competitive inhibitor of mTOR, Torin1,
induced autophagy in HeLa cells transfected with empty vector
or WT EGFR (Figures 2B–2D). In cells transfected with the active
EGFR mutants, L858R or D746–750, starvation and Torin1
induced lower levels of autophagy. However, active EGFR did
not block either starvation- or Torin1-induced mTOR deactiva-
tion (Figure 2D). Thus, active EGFRmutants suppress autophagy
in a manner that is partially independent of mTOR.
Active EGFR Mutants and EGF Stimulation of Wild-Type
EGFR Alter the Beclin 1 Interactome
The results above suggested that the EGFR/Beclin 1 interaction
may alter the Beclin 1-containing autophagy-inducing class III
PI3K complex. We mapped the EGFR binding domains of Beclin
1 in HeLa cells cotransfected with the active EGFR L858R
mutant and Beclin 1 truncation mutants (Figure S3). Amino acids
1–135, but not 1–115 of Beclin 1 coimmunoprecipitated with
active EGFR, suggesting that amino acids 115–135 containing1272 Cell 154, 1269–1284, September 12, 2013 ª2013 Elsevier Inc.the BH3 domain contribute to the interaction between Beclin 1
and EGFR. In addition, the evolutionarily conserved domain
(ECD) of Beclin 1 spanning from amino acids 244–377 was
sufficient to bind EGFR. Thus, Beclin 1 contains at least two
domains (the BH3 domain and the ECD domain) capable of bind-
ing to EGFR.
We hypothesized that EGFR binding enhances the interaction
of Beclin 1 with negative regulators such as Bcl-2 (which binds to
the Beclin 1 BH3 domain) and Rubicon (which binds to the Beclin
1 ECD) and diminishes the interaction of Beclin 1 with VPS34, the
class III PI3K involved in autophagosome initiation (which binds
to the Beclin 1 ECD) (He and Levine, 2010). Therefore, we exam-
ined the effects of expression of WT and active mutant EGFRs in
HeLa cells on the interaction between Beclin 1 and its binding
partners, Bcl-2, Rubicon, VPS34, UVRAG, and ATG14. Active
EGFR did not influence the interaction between Beclin 1 and
ATG14 or Beclin 1 and UVRAG. However, expression of either
of the active EGFR mutants (L858R or D746–750) increased
coimmunoprecipitation of Beclin 1 and Rubicon (Figure 3A)
and of Beclin 1 and Bcl-2 (Figure 3B). Conversely, cells express-
ing either of the active EGFR mutants had decreased
coimmunoprecipitation of Beclin 1 and VPS34 (Figure 3A). This
EGFR-regulated alteration in the Beclin 1 interactome was asso-
ciatedwith decreased Beclin 1-associated VPS34 kinase activity
(Figure 3C). EGF stimulation resulted in similar alterations in the
Beclin 1 interactome and a similar decrease in Beclin 1-associ-
ated VPS34 kinase activity in A549 NSCLC cells that express
WT EGFR (Figure 3D). Together, these data indicate that binding
of EGFR toBeclin 1 (either via ligand-dependent EGFR activation
or via activating mutations in EGFR) suppresses autophagy by
regulating the Beclin 1 interactome.
EGFR-Dependent Regulation of Autophagy and Beclin 1
Complex Formation in NSCLC Cells with Active EGFR
Mutants
We investigated whether this mechanism underlies EGFR regu-
lation of autophagy in NSCLC cells with activating mutations in
EGFR. We used two NSCLC lines: HCC827 cells have the
D746–750 EGFR activating mutation and are TKI-sensitive, and
H1975 cells have the L858R EGFR activating mutation and are
TKI-resistant due to a T790M mutation. First, we evaluated
whether TKI treatment induces autophagy; erlotinib blocked
the Beclin 1/EGFR interaction and increased GFP-LC3 puncta
in a dose-dependent manner in TKI-sensitive HCC827 cells
stably transfected with GFP-LC3, but not in TKI-resistant
H1975 cells stably transfected with GFP-LC3 (Figures 4A, 4B,
and 4F). Furthermore, HCC827 cells, but not H1975 cells,
demonstrated LC3-II conversion and p62 degradation after
erlotinib treatment (Figure 4C). Thus, TKI therapy disrupts the
EGFR/Beclin 1 complex and induces autophagy in TKI-sensitive,
but not TKI-resistant cells. This association between TKI sensi-
tivity and autophagy induction was also observed in vivo in tumor
xenografts formed by HCC827/GFP-LC3 and H1975/GFP-LC3
cells (Figures S4A–S4C); HCC827/GFP-LC3 xenografts had
increased autophagosomes after TKI treatment and underwent
complete regression within several days, whereas H1975/GFP-
LC3 xenografts did not have increased autophagosomes and
failed to respond to TKI treatment.
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Figure 2. Active EGFR Mutants Interact with Beclin 1 and Inhibit Autophagy Independently of mTOR
(A) Immunoprecipitation of EGFRwith anti-Flag in HeLa cells cotransfectedwith Flag-Beclin 1 and indicated EGFR plasmid. After O/N serum starvation, cells were
treated ± EGF (50 ng/ml, 30 min). Cells transfected with EGFR L858R were either treated with DMSO (Erlotinib ) or (1 mM, 4 hr) (Erlotinib +).
(B) Representative images of GFP-LC3 puncta in HeLa cells transfected with indicated plasmid, and grown in normal medium, subjected to amino acid starvation
(2 hr), or treated with Torin1 (50 ng/ml, 2 hr). Scale bar represents 20 mm.
(C) Quantification of GFP-LC3 puncta in conditions shown in (B). Bars are mean ± SEM of triplicate samples (R50 cells analyzed per sample). Similar results were
observed in three independent experiments. **p < 0.01, ***p < 0.001, one-way ANOVA for indicated comparison; ##p < 0.01, two-way ANOVA for comparison of
magnitude of changes between different groups.
(D) Western blot detection of p62 and LC3-I/II (to measure autophagy) and p-4E-BP1 (to measure mTOR activity).
See also Figure S2.Because erlotinib decreased mTOR activity in HCC827 cells,
as measured by phosphorylation of the mTOR substrate, 4E-
BP1 (Figure 4C), we asked whether erlotinib-induced autophagy
is dependent on suppression of mTOR. We transfected HCC827
cells with a constitutively active mTOR mutant S2215Y (Sato
et al., 2010) that blocks starvation-induced mTOR deactivation
and dephosphorylation of 4E-BP1. mTOR S2215Y expression
in HCC827 cells decreased levels of erlotinib-induced mTOR
and 4E-BP1 dephosphorylation but had no effect on erlotinib-
induced autophagy (Figures 4D and 4E). Thus, TKI-inducedCautophagy in a NSCLC cell line with an active EGFR mutation
is independent of mTOR deactivation.
We investigated whether TKI-induced autophagy in HCC827
cells involves regulation of the Beclin 1 interactome. In TKI-
sensitive HCC827 cells (but not in TKI-resistant H1975 cells),
erlotinib led to EGFR dephosphorylation, disruption of EGFR/
Beclin 1 binding, disruption of Beclin 1/Rubicon binding, in-
creased Beclin 1/VPS34 binding, decreased Beclin 1/Bcl-2 bind-
ing, and increased Beclin 1-associated VPS34 kinase activity
(Figures 4F–4H). Thus, TKI-induced autophagy in NSCLCs withell 154, 1269–1284, September 12, 2013 ª2013 Elsevier Inc. 1273
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(A) Immunoprecipitation of indicated proteins with
Beclin 1 in HeLa cells transfected with indicated
EGFR constructs.
(B) Immunoprecipitation of Beclin 1 with Bcl-2 in
HeLa cells transfected with indicated EGFR
constructs.
(C) Beclin 1-associated VPS34 in vitro kinase
assay in anti-Beclin 1 immunoprecipitates of HeLa
cells transfected with indicated EGFR constructs.
(D) EGF effects on the Beclin 1 interactome and
Beclin 1-associated VPS34 kinase activity in A549
cells. Cells cultured as in Figure 1Awere subjected
to immunoprecipitation with anti-Bcl-2 followed by
western blot detection of Beclin 1 or immunopre-
cipitation with anti-Beclin 1 followed by either
western blot detection of indicated proteins or a
VPS34 in vitro kinase assay.
See also Figure S3.active EGFR is associated with increased Beclin 1-associated
VPS34 kinase activity and disruption of the interaction between
Beclin 1 and EGFR and betweenBeclin 1 and negative regulators
of autophagy such as Bcl-2 and Rubicon. The effect of active
EGFR on Beclin 1/Bcl-2 and Beclin 1/VPS34 interactions is likely
indirect, as only Beclin 1 and Rubicon (but not Bcl-2, ATG14,
UVRAG, or VPS34) coimmunoprecipitate with active EGFR in
HCC827 cells (Figure 4I).
Mutational Activation of EGFR and Ligand Stimulation of
Wild-Type EGFR Results in Beclin 1 Tyrosine
Phosphorylation
We investigated whether regulation of Beclin 1 function by active
EGFR involves Beclin 1 tyrosine phosphorylation. Beclin 1 was
tyrosine phosphorylated in NSCLC cells with WT EGFR after
EGF stimulation (Figure 5D) and in NSCLC cells with active
EGFR mutations (HCC827 and H1975 cells) (Figure 5A). This
was decreased by erlotinib in TKI-sensitive HCC827 cells, but
not TKI-resistant H1975 cells. Inhibition of c-Met, another onco-
genic receptor tyrosine kinase activated in HCC827 cells, did not
block Beclin 1 tyrosine phosphorylation, and Beclin 1 did not
coimmunoprecipitate with active c-Met (Figures S5A and S5B).
This suggests that active EGFR (but not other receptor tyrosine
kinases) is responsible for Beclin 1 tyrosine phosphorylation in
HCC827 cells.
We identified sites of EGFR-mediated in vitro Beclin 1 phos-
phorylation using recombinant active EGFR L858R/T790M and
two synthetic peptides derived from regions of Beclin 1 contain-
ing three database-identified candidate tyrosine phosphoryla-
tion sites, Y229, Y233, and Y352. Active EGFR phosphorylated1274 Cell 154, 1269–1284, September 12, 2013 ª2013 Elsevier Inc.the Beclin 1 peptide spanning amino
acids 223–239 in a concentration-depen-
dent manner (Figure S5C), whereas con-
trol tyrosine kinases, including PDGFRb,
mutationally active PDGFRa T674I and
SRMS, did not (data not shown). Mutation
of both Y229 and Y233 was required toblock EGFR-dependent phosphorylation of the Beclin 1 amino
acid 223–239 peptide. The peptide spanning Y352 (Beclin 1
amino acids 345–358) underwent low levels of phosphorylation
at the highest peptide concentration examined. Thus, Beclin 1
Y229, Y233, and possibly Y352 may be substrates of EGFR-
mediated Beclin 1 tyrosine phosphorylation.
To evaluate whether Beclin 1 Y229, Y233, and/or Y352 are
required for Beclin 1 tyrosine phosphorylation in HCC827
NSCLC cells, we expressed Flag epitope-taggedWT andmutant
Beclin 1 constructs. Although the peptide spanning Beclin 1
Y352 was only mildly phosphorylated by active EGFR in vitro,
simultaneous mutation of all three candidate tyrosine phosphor-
ylation sites (Y229F, Y233F, and Y352F) in full-length Beclin 1
was required to block Beclin 1 tyrosine phosphorylation (Figures
5B and S5D). Thus, in NSCLC cells with active EGFR, three
Beclin 1 tyrosine residues—Y229, Y233, and Y352—are phos-
phorylated. These residues are conserved in Beclin 1 throughout
metazoan evolution (data not shown).
Flag-Beclin 1 Y233 phosphorylation was detected in HCC827
cells transfected withWT Flag-Beclin 1 but not with mutant Flag-
Beclin 1 Y233F using a phosphospecific antibody (Figure 5C).
Endogenous Beclin 1 Y233 phosphorylation was detected in
A549 cells expressingWTEGFRafter EGF stimulation (Figure 5D)
and in HCC827 and H1975 cells with active EGFR mutations
(Figure 5E). This phosphorylation was blocked by erlotinib in
HCC827, but not in H1975, cells. Thus, Beclin 1 Y233 phosphor-
ylation is regulated by ligand-dependent and ligand-indepen-
dent activation of EGFR. Furthermore, NSCLC cells with
activating mutations in EGFR (H1975, H3255, and HCC827)
had detectable Beclin 1 Y233 phosphorylation, whereas cells
with amplified wild-type EGFR (A549, H1703, H1819, and
H2073), with amplified c-Met (H1933) or with K-Ras mutation
(HCC4017, H2122) did not (Figure 5F), indicating that Beclin 1
Y233 phosphorylation may be a specific marker of mutationally
active EGFR in NSCLC.
To evaluate the functional consequences of Beclin 1 tyrosine
phosphorylation, we generated NSCLC cells that stably express
WT Flag-Beclin 1 or Flag-Beclin 1 containing three nonphos-
phorylatable mutations, Y229F/Y233F/Y352F (FFF) or three
phosphomimetic mutations, Y229E/Y233E/Y352E (EEE) (Fig-
ure 5G). Flag-Beclin 1 FFF interacted with active EGFR and its
interactome was regulated by EGFR inhibition in a manner
similar to that of WT Flag-Beclin 1. This most likely reflects the
presence of endogenous Beclin 1 in these cells (that is tyrosine
phosphorylated when EGFR is active) and the homodimerization
of Beclin 1 FFF with WT Beclin 1 (Figure 5H), as Beclin 1 homo-
dimerization is predicted to favor binding to Rubicon and Bcl-2
and disfavor binding to VPS34 (see model, Figure S5E). In
contrast, the phosphomimetic Beclin 1 EEE mutant escaped
regulation by TKI treatment; erlotinib resulted in dephosphoryla-
tion of EGFR (indicating preserved receptor sensitivity to TKIs)
but did not disrupt Beclin 1 EEE/EGFR, Beclin 1 EEE/Rubicon,
or Beclin 1/Bcl-2 interactions and did not increase the Beclin 1
EEE/VPS34 interaction or increase Beclin 1 EEE-associated
VPS34 kinase activity. In addition, unlike WT Beclin 1 or Beclin
1 FFF, the Beclin 1 EEE mutant dimerized with itself or with WT
Beclin 1 in HCC827 cells in the setting of EGFR inhibition (Fig-
ure 5H). Together, these findings indicate that the Beclin 1 EEE
mutant mimics tyrosine phosphorylated Beclin 1.
Perhaps via constitutive dimerization with endogenous WT
Beclin 1 (Figure 5H), Beclin 1 EEE functioned as a dominant
negative mutant of TKI-induced autophagy. Despite the pres-
ence of endogenous Beclin 1 in NSCLC cells, overexpression
of Beclin 1 EEE suppressed erlotinib-induced autophagy (Fig-
ure 5G). Thus, Beclin 1 tyrosine dephosphorylation (and disrup-
tion of Beclin 1 homodimerization) may be essential for
TKI-induced autophagy. Moreover, a lower level of basal
autophagy and Beclin 1-associated VPS34 kinase activity was
observed in non-TKI-treated HCC827 cells expressing Beclin 1
EEE. This suggests that constitutive Beclin 1 tyrosine phosphor-
ylation enhances autophagy suppression in cells with active
EGFR mutation.
A Beclin 1 Tyrosine Phosphomimetic Mutant Enhances
Autophagy Suppression, Tumor Growth, and Tumor
Dedifferentiation of NSCLC Xenografts
As Beclin 1 EEE expression in NSCLC cells enhanced autophagy
suppression in vitro, we evaluated the effects of Beclin 1 EEE
expression on NSCLC autophagy and tumor progression in vivo,
using a SCID/NOD mouse xenograft model. Beclin 1 EEE-
expressing NSCLC xenografts had lower levels of autophagy
(Figure 6A) and grew at a faster rate than those derived from
NSCLCs transfected with empty vector control, WT Beclin 1,
or Beclin 1 FFF (Figure 6B). Conversely, although there was no
difference in tumor volume on day 35 (Figure 6C), xenografts
from NSCLCs expressing either WT Beclin 1 or Beclin 1 FFF
grew at a slower rate than control xenografts (Figure 6B) and
had biochemical evidence of increased autophagy (Figure 6A).CThus, in human NSCLC xenografts with EGFR mutation,
changes in autophagic activity are associated with inverse
changes in the rates of tumor growth.
This inverse relationship seemingly contradicts the paradigm
that autophagy fosters the growth of established tumors
(Amaravadi et al., 2011; Rubinsztein et al., 2012). This protumor
function of autophagy is thought to be related to its role in
promoting cell survival in themetabolically stressed tumormicro-
environment, and indeed, we found that NSCLC xenografts with
increased autophagy had decreased cell death. NSCLC xeno-
grafts with overexpression of WT Flag-Beclin 1 or mutant Flag-
Beclin 1 FFF (that increased steady-state levels of autophagy)
had decreased numbers of TUNEL-positive cells, whereas
NSCLC xenografts with overexpression of mutant Flag-Beclin 1
EEE (that suppressed steady-state levels of autophagy) had
increased numbers of TUNEL-positive cells (Figures 6D and
6E). Thus, although autophagy exerts prosurvival effects in
established tumors, the amount of autophagy-dependent cell
survivalmaybe insufficient to determine tumor growth inNSCLC.
We observed other differences that may account for increased
tumor growth in NSCLC xenografts expressing the Beclin 1 tyro-
sine phosphomimetic mutant. NSCLC xenografts expressing
Beclin 1 EEE exhibited increased cell proliferation (Figure 6F).
Consistent with this increased proliferation, NSCLC xenografts
expressing Beclin 1 EEE also had an increase in variance of
nuclear DNA intensity, perimeter, and area (Figures S6A–S6C).
More entotic (cell-in-cell structures) and more multinucleated
cells were also observed in NSCLC xenografts expressing Beclin
1 EEE (Figures S6D–S6F). This increase in entotic and multinu-
cleated cells was not associated with an increase in variance
in DNA ploidy in cells with single nuclei, although NSCLC
xenografts expressing WT Beclin 1 or Beclin 1 FFF (which had
increased levels of autophagy) had a decreased variance in
DNA ploidy (Figure S6G).
In addition to the aforementioned features, histopathologic
analyses revealed significant morphologic differences in
NSCLCs xenografts expressing Beclin 1 EEE (Figures 6G and
6H). HCC827 cells were derived from a 39-year-old never-smok-
ing woman with primary lung adenocarcinoma (Gazdar and
Minna, 1996), and xenografts from control HCC827, HCC827/
Flag-Beclin 1, and HCC/Flag-Beclin 1 FFF cells displayed
characteristic features of lung adenocarcinomas with mutated
EGFR (Shim et al., 2011). They manifested varying degrees of
gland formation and cohesive clusters of pleomorphic epithelial
cells (admixed with clusters of smaller ovoid or spindle-shaped
cells) (Figure 6G). In contrast, HCC827/Flag-Beclin 1 EEE xeno-
grafts appeared more poorly differentiated; they lacked overt
glandular differentiation, hadmore infiltrative features, and tumor
infiltrates often exhibited a solid growth pattern with morpho-
logic characteristics suggesting squamous differentiation, i.e.,
large cells with centrally placed nuclei and increased amounts
of pale pink cytoplasm (low nucleus-cytoplasmic ratio). No dif-
ferences were observed among the NSCLC xenograft groups
in terms of immunostaining for the markers of epithelial to
mesenchymal transition, e-cadherin, and vimentin (data not
shown).
To confirm the change in differentiation status of HCC827/
Flag-Beclin 1 EEE tumors, we stained all xenografts for TTF-1,ell 154, 1269–1284, September 12, 2013 ª2013 Elsevier Inc. 1275
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Figure 4. Erlotinib-Induced Autophagy in NSCLC Cells Is Associated with Regulation of the Beclin 1 Interactome
(A) Representative images of GFP-LC3 puncta in NSCLC cell lines treated with indicated concentration of erlotinib (4 hr). Scale bar represents 20 mm.
(B) Quantitation of GFP-LC3 puncta in NSCLC cell lines treated as in (A). Bars are mean ± SEM of triplicate samples (R50 cells analyzed per sample). Similar
results were observed in three independent experiments. NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA for indicated comparison. ##p <
0.01; two-way ANOVA for comparison of magnitude of changes between different groups.
(C) Western blot detection of p62, LC3-I/II, and p-4E-BP1 in indicated cells ± erlotinib (1 mM, 2 hr).
(D) Quantitation of GFP-LC3 puncta in HCC827 cells transiently cotransfected with GFP-LC3 and control vector or a constitutively active mTORmutant (S2215Y)
and incubated ± DMSO (control) or erlotinib (1 mM, 2 hr). Bars are mean ± SEM of triplicate samples (R50 cells analyzed per sample). Similar results were
(legend continued on next page)
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p63, and cytokeratin 5 (CK5), which are used clinically to distin-
guish between lung adenocarcinoma and squamous carcinoma
(Rekhtman et al., 2011). All xenografts had diffuse low expres-
sion of p63 (a marker of squamous differentiation, but also ex-
pressed bymany lung adenocarcinomas) and lacked expression
of CK5 (a marker of squamous cell carcinoma) (data not shown).
In contrast, marked differences were observed in expression of
TTF-1, a homeodomain protein that is highly expressed in lung
adenocarcinomas and whose loss of expression is associated
with aggressive tumor behavior and decreased median survival
in patients with NSCLC (Saad et al., 2004; Tang et al., 2011).
All control HCC827, HCC827/Flag-Beclin 1, and HCC827/Flag-
Beclin 1 FFF xenografts displayed strong TTF-1 staining homo-
genously in nearly all tumor cells, whereas the majority of tumor
cells in HCC827/Flag-Beclin 1 EEE xenografts displayed either
weak or undetectable TTF-1 staining (Figure 6H). Using an
established pathological score for grading TTF-1 staining
(Saad et al., 2004), 10/10 xenografts were strongly positive in
the control HCC827, HCC827/Flag-Beclin 1, and HCC827/
Flag-Beclin 1 FFF groups, whereas 7/10 xenografts were weakly
positive and 3/10 xenografts were moderately positive in the
HCC827/Flag-Beclin 1 EEE group.
Thus, expression of a Beclin 1 tyrosine phosphomimetic in
NSCLC xenografts in mice results in decreased autophagy,
increased cellular proliferation, accelerated tumor growth, and
dedifferentiation from TTF-1-positive adenocarcinomas to
TTF-1-negative poorly differentiated tumors with features of
squamous differentiation. This phenotype is analogous to human
adenosquamous carcinoma, an NSCLC subtype associated
with a worse prognosis. Similar findings were observed in
NSCLC xenografts from three independent Beclin 1 EEE clones
(data not shown), indicating that their aggressive features do not
represent a clonal artifact.
Inhibition of TKI-Induced Autophagy in NSCLC
Xenografts Results in Resistance to TKI Therapy
We evaluated the effects of blocking TKI-mediated autophagy
on the response of NSCLCs to TKI therapy. Because constitutive
Beclin 1 EEE expression alters the natural history of HCC827
xenografts, we generated HCC827 cell lines that express tetra-
cycline-inducible WT Beclin 1 or Beclin 1 Y229E/Y233E/Y352
(EEE) to induce protein expression in established tumors imme-
diately prior to initiation of TKI therapy. We confirmed that doxy-
cycline induction of Beclin 1 EEE expression (but not of WT
Beclin 1) in HCC827 cells reduced levels of erlotinib-induced
autophagy (Figures 7A and 7B). The suppression of erlotinib-
induced autophagy by Beclin 1 EEE expression was associated
with an increase in clonogenic survival of HCC827 cells afterobserved in three independent experiments. NS, not significant, *p < 0.05, **p < 0.0
ANOVA for comparison of magnitude of changes between different groups.
(E) Western blot detection of p62, LC3-I/II, and p-4E-BP1 in HCC827 cells treate
(F) Immunoprecipitation of indicated Beclin 1 binding partners with Beclin 1
immunoprecipitation.
(G) Immunoprecipitation of Beclin 1 with Bcl-2 in the conditions in (F).
(H) Beclin 1-associated VPS34 in vitro kinase assay after immunoprecipitation of
(I) Immunoprecipitation of indicated proteins with EGFR in HCC827 cells. Ce
immunoprecipitation.
See also Figure S4.
Ctreatment with erlotinib (Figure 7C). A similar increase in clono-
genic survival was also observed in erlotinib-treated HCC827
cells with ATG7 siRNA knockdown (Figures S7A and S7B), sug-
gesting that autophagy suppression, rather than other potential
effects of Beclin 1 EEE expression, contributes to TKI-resis-
tance. Similarly, selective inhibition of autophagy (without inhibi-
tion of apoptosis) by a mutant viral Bcl-2 (M11 AAA) protein that
binds to Beclin 1, but not Bax, increased HCC827 clonogenic
survival following treatment with erlotinib (Figures S7C–S7G).
We confirmed that these effects of autophagy suppression
in vitro on NSCLC resistance to TKI therapy also occurred in vivo,
using xenografts derived from HCC827 cells expressing tetracy-
cline-inducible Beclin 1 EEE and from HCC827 cells expressing
the mutant viral Bcl-2 protein. In HCC827 xenografts, induced
expression of Beclin 1 EEE (Figure 7D) decreased numbers of
autophagosomes 1 day after initiation of erlotinib (Figures 7E
and 7F) and resulted in partial resistance to erlotinib (Figure 7G).
In untreated control mice and in mice with induced expression of
WT Beclin 1, there was complete regression of all tumor xeno-
grafts within 14 days (Figure 7G). In contrast, xenografts with
induced expression of Beclin 1 EEE had a slower rate of tumor
regression and all tumors remained at the end of the 28 day
observation period. Similarly, xenografts derived from HCC827
cells expressing the viral Bcl-2 inhibitor of autophagy had
decreased erlotinib-induced autophagy and were partially resis-
tant to erlotinib (Figures S7H–S7J). Together, these results
suggest that Beclin 1 tyrosine phosphorylation and autophagy
suppression contribute to TKI resistance in NSCLCs with
EGFR mutations.
DISCUSSION
Active EGFR Suppresses Autophagy through Beclin 1
Tyrosine Phosphorylation
The Beclin 1/VPS34 complex plays a crucial role in autophago-
some formation. Moreover, Beclin 1 is emerging as a central
node of autophagy regulation via cross-talk with diverse cellular
and viral autophagy stimulatory or inhibitory proteins; such
cross-talk allows the integration of diverse environmental cues
with levels of cellular autophagy. Although it was known that
activation of cell surface receptors involved in growth factor
signaling suppresses autophagy, the precise mechanisms
underlying such suppression have been poorly understood.
Here, we demonstrate that upon activation, EGFR interacts
with Beclin 1, promoting its tyrosine phosphorylation and inacti-
vation. This effect occurs in cells expressingWTEGFR upon EGF
binding as well as in human NSCLC cells with activating cancer-
driving mutations in EGFR. Thus, EGFR signaling suppresses1, ***p < 0.001; one-way ANOVA for indicated comparison. ##p < 0.01; two-way
d as in (D).
in HCC827 and H1975 cell lines incubated ± erlotinib (1 mM, 4 hr) prior to
Beclin 1 complexes from indicated cells ± erlotinib (1 mM, 4 hr).
lls were incubated in medium with DMSO or erlotinib (1 mM, 2 hr) prior to
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Figure 5. EGFR-Mediated Tyrosine Phosphorylation of Beclin 1 Regulates the Beclin 1 Interactome
(A) Western blot detection of Beclin 1 tyrosine phosphorylation in NSCLC cells ± erlotinib (1 mM, 2 hr). Lysates were immunoprecipitated with an anti-Beclin 1
followed by western blot analysis with an antiphosphotyrosine antibody (pY99).
(B) Beclin 1 phosphotyrosine site identification. HCC827 cells transfected withWT or indicatedmutant Flag-Beclin 1 constructs were immunoprecipitated with an
anti-Flag followed by western blot analysis with anti-pY99.
(C) Specificity of phospho-Beclin 1 Y233 antibody. HCC827 cells transfected withWT ormutant Flag-Beclin 1 constructs were immunoprecipitated with anti-Flag
followed by western blot analysis with anti-Beclin 1 pY233.
(D) Western blot detection of phospho-Beclin 1 Y233 in A549 cells cultured as in Figure 3D. Lysates from same experiment were immunoprecipitated with anti-
Beclin 1 followed by western blot analysis with anti-pY99 or antiphospho-Beclin 1 Y233.
(E) Western blot detection of phospho-Beclin 1 Y233 in NSCLC cells ± erlotinib (1 mM, 4 hr). Lysates were immunoprecipitated with anti-Beclin 1 followed by
western blot analysis with anti-phospho-Beclin 1 Y233.
(legend continued on next page)
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autophagy via its interaction with Beclin 1 during normal mito-
genic signaling as well as during aberrant cell proliferation in
cancer cells.
These findings directly link receptor tyrosine kinases involved
in cell growth control and autophagy suppression. Several
downstreammolecules in the EGFR signaling pathway, including
PI3K, Akt, and mTOR, are known to negatively regulate autoph-
agy (Botti et al., 2006). Our results uncover a new mechanism of
EGFR suppression of autophagy that is mTOR independent—
involving an interaction between EGFR and the Beclin 1 autoph-
agy protein—that underscores the importance of autophagy
suppression by EGFR signaling. Although we did not find evi-
dence of EGFR-independent Beclin 1 tyrosine phosphorylation
in NSCLC cells with active EGFR mutations, other members of
the EGFR family (e.g., HER2, HER3, HER4) and/or other onco-
genic receptor tyrosine kinases may also inactivate Beclin 1
and the autophagy pathway in other cell types.
The mechanism by which EGFR suppresses Beclin 1 function
involves EGFR interaction with two domains (BH3 and ECD) of
Beclin 1; EGFR-mediated multisite tyrosine phosphorylation of
Beclin 1 on residues Y229, Y233, and Y352; and EGFR-mediated
alterations in the Beclin 1 interactome (increased binding to the
negative regulators, Bcl-2 and Rubicon, and decreased binding
to the VPS34 lipid kinase). The interaction between EGFR and
Beclin 1 most likely occurs in endosomes, the site of EGFR
signaling following ligand-dependent internalization (with WT
EGFR) and of kinase domain mutants that promote constitutive
activation and constant endocytic internalization (Wang et al.,
2002). Active EGFR interacts with Beclin 1 and Rubicon, but
not other Beclin 1 binding partners, such as Bcl-2, VPS34,
UVRAG, or ATG14. Thus, the regulation of the Beclin 1 interac-
tome (increased Beclin 1/Bcl-2 binding and decreased Beclin
1/VPS34 binding) by EGFR-mediated phosphorylation is indi-
rect. Our data showing that Beclin 1 tyrosine phosphorylation
promotes Beclin 1 homodimerization suggests a model (sup-
ported by the crystal structures of the Beclin 1 coiled coil region
and evolutionarily conserved domain) in which EGFR-mediated
Beclin 1 tyrosine phosphorylation favors the formation of Beclin
1 dimers that are unable to bind VPS34 and promote autophagy
(Figure S5E). In addition to blocking autophagy, we speculate
that EGFR-mediated Beclin 1 tyrosine phosphorylation may
also block its own endolysosomal degradation by promoting
the binding of Rubicon to tyrosine phosphorylated Beclin 1, as
Rubicon inhibits EGF-stimulated EGFRdegradation in A549 cells
(Matsunaga et al., 2009). Thus, activating mutations in EGFR
may exert multiple effects on Beclin 1; EGFR-dependent Beclin
1 tyrosine phosphorylation may both suppress its autophagy
activity as well as its role in endolysosomal trafficking.(F) Western blot detection of phospho-Beclin 1 Y233 in NSCLC cell lines with or w
See text for information on cell lines.
(G) Immunoprecipitation of Beclin 1 binding partners with WT and indicated Flag-B
2 hr). Lysateswere immunoprecipitatedwith anti-Bcl-2 or anti-Flag and subjected
were also used to measure Beclin 1-associated VPS34 in vitro kinase activity (lo
(H) Effect of Beclin 1 tyrosine phosphorylation site mutations on EGFR-regulated
Flag and western blot analysis with indicated antibodies of HCC827 cells cotransf
tagged Beclin 1 constructs ± erlotinib (1 mM, 2 hr).
WT, wild-type Flag-Beclin 1; FFF, Flag-Beclin 1 Y229F/Y233F/Y352F; EEE, Flag
CEGFR Suppression of Beclin 1 May Contribute to Tumor
Progression in NSCLC
Several lines of evidence indicate that decreased Beclin 1 func-
tion contributes to tumor initiation: allelic loss of beclin 1 in-
creases the incidence of spontaneous malignancies in mice,
Akt-mediated phosphorylation of Beclin 1 contributes to Akt-
fibroblast transformation, and allelic loss of beclin 1 in immortal-
ized mammary epithelial cell lines enhances their tumorigenesis
in vivo (Levine and Kroemer, 2008; Wang et al., 2012). However,
to date, it has been unclear whether loss of Beclin 1 function con-
tributes to the progression of established tumors. Our present
findings suggest that enhanced Beclin 1 inactivation (via consti-
tutive expression of a tyrosine phosphomimetic mutant) aug-
ments tumor growth of existing NSCLCs with active EGFR
mutation. In addition to accelerated growth and increased cell
proliferation, tumors with expression of the Beclin 1 tyrosine
phosphomimetic have histopathologic features indicative of a
dedifferentiated, more aggressive neoplasm, including squa-
mous differentiation, increased infiltration, and loss of TTF-1
expression. Because activating EGFR mutations in NSCLC
result in constitutive Beclin 1 tyrosine phosphorylation, we
postulate that endogenous Beclin 1 tyrosine phosphorylation in
NSCLCs may similarly contribute to tumor progression.
We cannot definitively conclude that inactivation of the
autophagy function of Beclin 1, rather than its other potential
membrane-trafficking functions, contributes to tumor progres-
sion in NSCLCs expressing the Beclin 1 tyrosine phosphomi-
metic mutant. As Beclin 1-associated VPS34 kinase activity is
likely essential for both autophagy and other membrane-
trafficking events, it is difficult to genetically separate these func-
tions. Nonetheless, we observed a strong relationship between
Beclin 1 tyrosine phosphorylation and autophagy suppression
in NSCLCs. EGF stimulation suppressed autophagy in NSCLCs
expressing WT EGFR; cell lines with constitutive mutations in
EGFR had constitutive Beclin 1 tyrosine phosphorylation and
autophagy suppression; cell lines with EGFR TKI-sensitivemuta-
tions, but not with EGFR TKI-resistant mutations, decreased
Beclin 1 tyrosine phosphorylation and autophagy suppression
following TKI treatment; and overexpression of a Beclin 1 tyro-
sine phosphomimetic mutant in TKI-sensitive EGFR mutant
NSCLC cells enhanced autophagy suppression.
Regardless of whether Beclin 1 tyrosine phosphorylation func-
tions to enhance tumor progression via suppression of autoph-
agy or some other Beclin 1/VPS34-dependent trafficking
event(s), our results reveal an important principle regarding the
interrelationship between autophagy, cell survival, and tumor
progression. We observed decreased cell death in NSCLCs
with increased autophagy (i.e., thoseoverexpressingWTBeclin 1ithout active EGFR mutations. Phospho-Beclin 1 Y233 was detected as in (E).
eclin 1 mutant constructs in stably transfected HCC827 cells ± erlotinib (1 mM,
towestern blot analysis with indicated antibodies. Beclin 1 immunoprecipitates
wer panel).
Beclin 1 dimerization and binding to Rubicon. Immunoprecipitation with anti-
ected with indicated Flag epitope-tagged Beclin 1 constructs andMyc epitope-
-Beclin 1 Y229E/Y233E/Y352E. See also Figure S5.
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Figure 6. Beclin 1 Tyrosine Phosphorylation Is Associated with Enhanced Tumorigenesis In Vivo
(A) Western blot analysis of autophagy (p62 and LC3), EGFR activity (p-EGFR), and mTOR activity (p-4E-BP1) in indicated xenografts (three randomly chosen
samples per condition; similar results observed in all ten samples per condition).
(B) Tumor volume of xenografts formed after subcutaneous injection of NOD SCID mice with HCC827 cells stably transfected with indicated Beclin 1 constructs.
Results are mean volume ± SEM for ten mice per group per time point. p < 0.0001 for EEE versus control; p = 0.0006 for WT versus control; p = 0.0074 for FFF
versus control; linear-mixed effect model.
(C) Tumor weights from experiment in (B) upon autopsy at day 35. NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA.
(D) Representative images of TUNEL-labeling of indicated HCC827 xenograft tumor genotype. Black arrow denotes representative TUNEL-positive cell.
(legend continued on next page)
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or a nonphosphorylatable mutant of Beclin 1, Beclin 1 Y229F/
Y233F/Y352F), and we observed increased cell death in
NSCLCs with decreased autophagy (i.e., those overexpressing
a tyrosine phosphomimetic mutant of Beclin 1, Beclin 1 Y229E/
Y233E/Y352E). These results are consistent with previous
studies demonstrating that autophagy functions as a pro-
survival pathway in the metabolically stressed tumor microenvi-
ronment (Amaravadi et al., 2011; Rubinsztein et al., 2012).
However, at least in NSCLCs, the amount of cell death may
not be the primary determinant of tumor progression. Other pre-
viously described antitumor functions of autophagy such as pre-
venting DNA damage and chromosomal instability and limiting
cell proliferation (Levine and Kroemer, 2008) and/or other effects
of Beclin 1 such as the prevention of tumor dedifferentiation, may
prevail over the prosurvival effects of autophagy in limiting tumor
progression. Our observation that tumors with the least autoph-
agy and the greatest amount of cell death also were the most
aggressive (in terms of growth rate and histopathology) raise
important questions about the strategy of inhibiting autophagy
in cancer simply because it can function as a prosurvival
pathway. Although such strategies may increase tumor cell
death, they may promote tumor progression by blocking other
autophagy-dependent functions.
NSCLC Response to EGFR TKI Therapy May Involve
Activation of Beclin 1 and Autophagy
Our results have direct implications for the treatment of patients
with active EGFR mutations and NSCLC. Based on previous
data that EGFR TKIs induce autophagy (Gorzalczany et al.,
2011; Han et al., 2011) and the belief that autophagy induction
may lead to chemoresistance (Amaravadi et al., 2011), there
are currently several NIH-sponsored clinical trials that combine
autophagy inhibitory agents (e.g., chloroquine and hydroxy-
chloroquine) with EGFR inhibitors in the treatment of NSCLC.
Earlier studies have either claimed that autophagy induction
can enhance or limit the response to EGFR TKI therapy, but
they suffer from experimental limitations, including (1) the use
of NSCLC cell lines with WT EGFR or overexpressed EGFR
rather thanNSCLCswith TKI-sensitivemutations in EGFR (which
are the tumors that clinically respond best to TKI therapy), (2) in-
duction of autophagy with the use of high doses of TKIs, which
are not relevant to those prescribed to patients, (3) the use of
assays based on mitochondrial activity (which reflect both cell
proliferation and death) rather than clonogenic survival assays
to determine the effect of autophagy manipulation on NSCLC
survival, and most importantly (4) the lack of in vivo studies
that directly assess the effects of modulating autophagy on the
response of NSCLC to TKIs. By contrast, we assessed clono-
genic survival of NSLCs cells with an active mutation in EGFR
after treatment with a clinically relevant concentration of erlotinib
using three complementary approaches to inactivate erlotinib-
induced autophagy: expression of a Beclin 1 tyrosine phospho-(E and F) Quantitation of TUNEL-positive nuclei (E) and Ki67-positive nuclei (F) in in
genotype (10 per group), from 30 randomly selected fields for each tumor. NS, n
(G) Representative hematoxylin and eosin staining (H&E) images of indicated HC
(H) Representative images of TTF-1 immunostaining in indicated HCC827 xenog
Scale bars represent 20 mm. See also Figure S6.
Cmimetic, expression of a viral Bcl-2 mutant that selectively
inhibits autophagy, but not apoptosis, and siRNA knockdown
of an autophagy gene ATG7 that functions downstream of
Beclin 1. In all these studies, autophagy inhibition was associ-
ated with increased clonogenic survival and TKI resistance
in vitro. Moreover, in tumor xenografts formed by TKI-sensitive
NSCLC cells, TKI resistance was conferred either by expression
of a viral Bcl-2 autophagy inhibitor or inducible expression of the
Beclin 1 tyrosine phosphomimetic mutant that blocks autoph-
agy. Together, our data suggest that (1) autophagy induction
contributes to EGFR TKI responses in NSCLCs with active
EGFR mutations, and (2) the use of autophagy inhibitors in
patients receiving EGFR TKIs may adversely (rather than favor-
ably) affect their clinical course.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
HeLa and the NSCLC tumor cell lines were grown in RPMI-1640 medium
(Invitrogen) with 10% fetal bovine serum (FBS) (Invitrogen). A549, HCC827,
and H1975 cell lines stably transfected with GFP-LC3 and/or Beclin 1 expres-
sion constructs were generated as described in the Extended Experimental
Procedures.
Antibodies, Plasmids, and Reagents
pTyr233-Beclin 1 antibody was custom-produced by PhosphoSolutions. See
the Extended Experimental Procedures for details of other antibodies, plas-
mids, and reagents.
Coimmunoprecipitation and Western Blot Analyses
Beclin 1, EGFR, or Bcl-2 complexes were immunoprecipitated in HeLa cells,
A549 cells, HCC827 cells in the presence or absence of 50 ng/ml EGF, or
1 mM erlotinib as described in the Extended Experimental Procedures, and
western blot analyses were performed on the immunoprecipitates to detect
Beclin 1, EGFR, phospho-EGFR, phospho-Beclin 1, Bcl-2, VPS34, ATG14,
Rubicon, and UVRAG.
VPS34 and EGFR In Vitro Kinase Assays
Beclin 1-VPS34 complexes were immunoprecipitated with anti-Beclin 1 from
A549, HeLa or HCC827 cells and used as substrates for a VPS34 in vitro kinase
assay (Wanget al., 2012). To identify the tyrosinephosphorylationsitesofBeclin
1, an in vitro peptide kinase assay was performed by ProQinase GmbH
(Freiburg, Germany) as described in the Extended Experimental Procedures.
Autophagy Assays
Autophagy was measured by quantitation of GFP-LC3 puncta using fluores-
cence microscopy in cells and tumor xenografts by an observed blinded to
experimental condition and by western blot analysis of LC3 and p62 in cell
and tissue lysates.
Immunostaining
Immunofluorescence staining of HeLa cells was performed to detect EGFR,
Flag-Beclin 1, EEA1, Lamp1, and Tom20 and the images were analyzed on
a Zeiss AxioImager Z2 microscope. Immunoperoxidase staining to detect
TTF-1 and Ki67 expression and TUNEL staining to detect apoptotic cells
was performed on tumor xenograft sections. See the Extended Experimental
Procedures for details.dicated xenograft tumor genotype. Bars are mean + SEM for all tumors in each
ot significant, *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA.
C827 xenograft tumor genotypes. See text for description.
raft tumor genotype.
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Tumor Xenograft Studies
Six-week-old NODSCIDmicewere injected subcutaneously in the flank region
with 107 NSCLC (HCC827) tumor cells, and tumor volume was measured daily
using the formula (tumor volume = ½(L 3W2)) for 35 days. To measure tumor
response to erlotinib therapy, mice were randomized after tumors reached
400 mm3 to receive water containing either 2 mg ml1 doxycycline or no
doxycycline and beginning 3 days later, treated daily with 12.5 mg kg1 intra-
peritoneal erlotinib until tumors were no longer detectable or for a maximum of
28 days. All animal procedures were performed in accordance with institu-
tional guidelines and with approval from the Institutional Animal Care and
Use Committee. See the Extended Experimental Procedures for details.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
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